INTERVIEW

Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO

April 5, 2017
As Takeda Pharmaceutical reworked its R&D strategies, the company pondered what to do with its renal, metabolic, and cardiovascular pipelines that might be promising but are no longer its core area. The answer was to split off eight ongoing projects…

To read the full story

Related Article

INTERVIEW

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

By Philip Carrigan

Watching a master craftsman at work is a sight to behold.With confidence forged over years of practice, complicated steps appear effortless, problems are smoothly managed, and the final product is perfect, in every sense of the word. Within each of…